<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00592631</url>
  </required_header>
  <id_info>
    <org_study_id>0405-16</org_study_id>
    <secondary_id>0405-16</secondary_id>
    <nct_id>NCT00592631</nct_id>
  </id_info>
  <brief_title>Assessment Of The Effects Of Short and Long Term Use Of CPAP</brief_title>
  <official_title>Assessment of the Effects of Short and Long Term Use of Continuous Positive Airway Pressure on Airway Reactivity in Children and Adults With and Without Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize that the nocturnal use of continuous positive airway pressure in adults and
      children with asthma will decrease airway reactivity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Deep inspirations have been shown to decrease the sensitivity of airways to narrowing (airway
      reactivity) after inhalation of agents that induce constriction of the bronchi in healthy
      adults. This response is absent in adult asthmatics; however, there is data demonstrating
      that use of continuous positive airway pressure (CPAP) for short periods of time may decrease
      airway reactivity in adult asthmatics. This suggests that although deep inspirations may not
      result in decreased airway reactivity, sustained lung inflation may lead to changes in
      asthmatic airway smooth muscle structure that lead to a decrease in airway reactivity. The
      purpose of our study is to determine whether short and long term use of CPAP in children and
      adults leads to decreased airway reactivity. If airway reactivity is decreased with CPAP,
      this may provide a novel therapeutic strategy for patients with asthma.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Key investigator resigned
  </why_stopped>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Provocative Concentration of Methacholine Causing a 20% Fall in Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>7 to 10 nights after cpap is started.</time_frame>
    <description>Methacholine is an inhaled medication used to assess asthma and reactive airways. It was given at increasing concentrations (beginning with 0.0625 mg/ml and ending with 16.0 mg/ml). Each dose was followed by a lung measurement until a change of FEV1 of 20% occurs or until a maximum dose was reached, whichever came first.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>CPAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use CPAP of 8-12 during days 2 through 6 of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHAM</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Subjects will use sham CPAP of 0-2 during days 2 through 6 of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CPAP-Continuous Positive Airway Pressure</intervention_name>
    <description>Cpap will be worn at night by subjects 6 to 7 days duration.</description>
    <arm_group_label>CPAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SHAM</intervention_name>
    <description>SHAM will be worn at night by subjects 6 to 7 days duration.</description>
    <arm_group_label>SHAM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion criteria for children 8-18

          -  Children 8-18 years of age scheduled to start CPAP for obstructive sleep apnea.

          -  Subjects can have clinically stable asthma, with no plans by their physician to change
             asthma therapy over the next month

        Inclusion criteria adults 18-60

          -  Adults 18-60 years of age, seen in adult Pulmonary Clinic for sleep related problems
             who may require treatment with nocturnal continuous positive pressure (CPAP), which
             will be determined by polysomnography(PSG) will be approached to participate in the
             study.

        Exclusion Criteria:

        Exclusions for Children category age 8-18 include:

          1. Cyanotic congenital heart disease.

          2. History of acute respiratory symptoms for 3 weeks prior to testing.

          3. Inability to perform pulmonary function testing adequately.

          4. Escalation in asthma medication at time of recruitment.

          5. SaO2 &lt;93% while awake and breathing room air

          6. Baseline FEV1 &lt;75% predicted

        Exclusions for adults 18-60 include:

          1. Gastro-Esophageal Reflux requiring Medical management.

          2. Chronic Obstructive Pulmonary Disease.

          3. Use of Supplemental Oxygen.

          4. Ischemic Heart Disease or Hypertension requiring treatment with medications other than
             diuretics.

          5. Use of systemic corticosteroid therapy during the past 6 months.

          6. Acute Respiratory Illness in the previous 8 weeks.

        Exclusions/Inclusion criteria for adults with asthma include:

          1. Juniper Score &lt;1.5

          2. Baseline FEV1 &gt; or equal to 70%

          3. Non-smoking for 6 months

          4. Less than 10 pack year smoking history

          5. No change in asthma medications for the last 2 months

          6. Negative pregnancy test

          7. Subject cannot have sleep apnea
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert S. Tepper, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mike Busk, MD</last_name>
    <role>Study Director</role>
    <affiliation>NIFS/ Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2008</study_first_submitted>
  <study_first_submitted_qc>January 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2008</study_first_posted>
  <results_first_submitted>November 12, 2015</results_first_submitted>
  <results_first_submitted_qc>January 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 10, 2016</results_first_posted>
  <last_update_submitted>January 12, 2016</last_update_submitted>
  <last_update_submitted_qc>January 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>asthma</keyword>
  <keyword>sleep apnea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Continuous Positivie Airway Pressure</title>
          <description>Adult with stable asthma and normal spirometry used CPAP with a mask pressure between 8 and 10 cm H20 for 7 to 10 nights prior to the follow-up assessment.</description>
        </group>
        <group group_id="P2">
          <title>Sham Treatment</title>
          <description>Adults with stable asthma and normal spirometry used SHAM with a mask pressure Mask pressure between 0 and 2 cm H20 for 7 to 10 nights prior to the follow-up assessment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CPAP</title>
          <description>Subjects used CPAP set at 8-10 cmH20 for 7-10 nights.</description>
        </group>
        <group group_id="B2">
          <title>Sham</title>
          <description>Subjects used SHAM set at 0-2 cmH20 for 7-10 nights</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" spread="6"/>
                    <measurement group_id="B2" value="32" spread="9"/>
                    <measurement group_id="B3" value="29" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Provocative Concentration of Methacholine Causing a 20% Fall in Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Methacholine is an inhaled medication used to assess asthma and reactive airways. It was given at increasing concentrations (beginning with 0.0625 mg/ml and ending with 16.0 mg/ml). Each dose was followed by a lung measurement until a change of FEV1 of 20% occurs or until a maximum dose was reached, whichever came first.</description>
        <time_frame>7 to 10 nights after cpap is started.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CPAP</title>
            <description>Subjects used CPAP set at 8-10 cmH20 for 7-10 nights.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Subjects used sham set at 0-2 cmH20 for 7-10 nights</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Provocative Concentration of Methacholine Causing a 20% Fall in Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Methacholine is an inhaled medication used to assess asthma and reactive airways. It was given at increasing concentrations (beginning with 0.0625 mg/ml and ending with 16.0 mg/ml). Each dose was followed by a lung measurement until a change of FEV1 of 20% occurs or until a maximum dose was reached, whichever came first.</description>
          <units>log mg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.406" spread="0.066"/>
                    <measurement group_id="O2" value="0.003" spread="0.193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Continuous Positive Airway Pressure</title>
        </group>
        <group group_id="E2">
          <title>Sham</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Tepper, MD, Ph.D.</name_or_title>
      <organization>Indiana University</organization>
      <phone>317-274-9647</phone>
      <email>rtepper@iu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

